• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Next generation sequencing for biliary tract cancers.用于胆管癌的下一代测序
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):471-474. doi: 10.1080/17474124.2021.1896967. Epub 2021 Mar 10.
2
Translating cancer genomics for precision oncology in biliary tract cancers.将癌症基因组学转化应用于胆管癌的精准肿瘤学。
Discov Med. 2019 Nov-Dec;28(155):255-265.
3
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.靶向测序在晚期胆道癌患者管理中的治疗相关性：DNA 损伤修复基因突变作为预测生物标志物。
Eur J Cancer. 2019 Oct;120:31-39. doi: 10.1016/j.ejca.2019.07.022. Epub 2019 Aug 30.
4
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.胆管癌患者的胚系改变：一系列重要且以前被低估的发现。
Cancer. 2020 Jan 1;126(9):1995-2002. doi: 10.1002/cncr.32740. Epub 2020 Feb 3.
5
Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.胆道癌患者微生物环境的潜在影响及其治疗意义。
Br J Cancer. 2022 Mar;126(5):693-705. doi: 10.1038/s41416-021-01583-8. Epub 2021 Oct 18.
6
Genomics driven precision oncology in advanced biliary tract cancer improves survival.基因组驱动的精准肿瘤学在晚期胆道癌中的应用提高了生存率。
Neoplasia. 2023 Aug;42:100910. doi: 10.1016/j.neo.2023.100910. Epub 2023 May 31.
7
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.胆管癌的基因组分析及其对临床实践的意义。
Curr Treat Options Oncol. 2016 Nov;17(11):58. doi: 10.1007/s11864-016-0432-2.
8
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.胆道癌的全面基因组景观和精准治疗方法。
Int J Cancer. 2021 Feb 1;148(3):702-712. doi: 10.1002/ijc.33230. Epub 2020 Aug 28.
9
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.胆囊癌的基因组学：生物标志物驱动的临床试验设计理由
Cancer Metastasis Rev. 2016 Jun;35(2):263-75. doi: 10.1007/s10555-016-9602-8.
10
New genomic landscapes and therapeutic targets for biliary tract cancers.胆管癌的新基因组图谱和治疗靶点。
Front Biosci (Landmark Ed). 2016 Jan 1;21(4):707-18. doi: 10.2741/4416.

引用本文的文献

1
Applications of 3D models in cholangiocarcinoma.3D模型在胆管癌中的应用。
Front Oncol. 2025 Jul 31;15:1598552. doi: 10.3389/fonc.2025.1598552. eCollection 2025.
2
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel.肝内胆管癌：多学科专家小组对分子检测、靶向治疗及未来方向的见解
Hepatol Commun. 2025 Jun 9;9(7). doi: 10.1097/HC9.0000000000000743. eCollection 2025 Jul 1.
3
Occupational and Environmental Cholangiocarcinoma-Related Toxic Exposures.职业性和环境性与胆管癌相关的有毒暴露
GE Port J Gastroenterol. 2024 Nov 7;32(3):151-160. doi: 10.1159/000541868. eCollection 2025 Jun.
4
Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers.推进精准医学：基因检测与测序技术在识别罕见癌症生物标志物中的作用
Cancer Med. 2025 Apr;14(8):e70853. doi: 10.1002/cam4.70853.
5
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.利用患者来源的异种移植模型来模拟胆管癌的精准肿瘤学。
Clin Cancer Res. 2025 Jan 17;31(2):387-402. doi: 10.1158/1078-0432.CCR-24-1233.
6
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.抗体药物偶联物及其在胆管癌患者治疗中的潜力。
Cancers (Basel). 2024 Sep 30;16(19):3345. doi: 10.3390/cancers16193345.
7
Treatment of Resectable Gallbladder Cancer.可切除胆囊癌的治疗
Cancers (Basel). 2022 Mar 10;14(6):1413. doi: 10.3390/cancers14061413.
8
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma.分子特征性肝内胆管癌消融放疗后的疗效基准评估
J Pers Med. 2021 Dec 1;11(12):1270. doi: 10.3390/jpm11121270.

本文引用的文献

1
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.晚期胆管癌的循环肿瘤DNA分析
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00324.
2
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.基因组分析揭示胆囊癌中 DNA 修复基因异常的高频发生。
Sci Rep. 2020 Dec 16;10(1):22087. doi: 10.1038/s41598-020-77939-6.
3
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.胆道癌循环肿瘤 DNA：当前证据和未来展望。
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441-452. doi: 10.21873/cgp.20203.
4
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.用于转移性癌症患者的下一代测序（NGS）的推荐意见：来自 ESMO 精准医学工作组的报告。
Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020 Aug 24.
5
Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.达拉非尼联合曲美替尼治疗携带 BRAF 突变的胆道癌患者（ROAR）：一项 2 期、开放标签、单臂、多中心篮子试验。
Lancet Oncol. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17.
6
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.在晚期实体瘤患者中进行的 Futibatinib（一种高度选择性、不可逆的 FGFR1-4 抑制剂）的 I 期首次人体研究。
Ann Oncol. 2020 Oct;31(10):1405-1412. doi: 10.1016/j.annonc.2020.06.018. Epub 2020 Jul 2.
7
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
8
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
9
Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.胆管癌循环肿瘤 DNA 的基因分型揭示了诊断和预后信息。
Sci Rep. 2019 Sep 13;9(1):13261. doi: 10.1038/s41598-019-49860-0.
10
Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.曲妥珠单抗和帕妥珠单抗在循环肿瘤DNA ERBB2扩增的HER2阳性难治性胆管癌中的应用
NPJ Precis Oncol. 2019 Aug 19;3:19. doi: 10.1038/s41698-019-0091-4. eCollection 2019.

Next generation sequencing for biliary tract cancers.

作者信息

DiPeri Timothy P, Javle Milind M, Meric-Bernstam Funda

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Expert Rev Gastroenterol Hepatol. 2021 May;15(5):471-474. doi: 10.1080/17474124.2021.1896967. Epub 2021 Mar 10.

DOI:10.1080/17474124.2021.1896967
PMID:33641586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8172427/
Abstract
摘要